Dominique Béchade, Lola-Jade Palmieri, Benjamin Bonhomme, Simon Pernot, Jeanne Léna, Marianne Fonck, Sophie Pesqué, Gautier Boillet, Antoine Italiano, Gilles Roseau
{"title":"回波内镜超声胰腺癌诊断和治疗方法：日常实践中是否应推荐 KRAS 基因突变研究？","authors":"Dominique Béchade, Lola-Jade Palmieri, Benjamin Bonhomme, Simon Pernot, Jeanne Léna, Marianne Fonck, Sophie Pesqué, Gautier Boillet, Antoine Italiano, Gilles Roseau","doi":"10.1177/17562848231224943","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The impact of <i>KRAS</i> mutation testing on pancreatic ductal adenocarcinoma (PDAC) samples by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for reducing the need to repeat EUS-FNA has been demonstrated. Such testing however is not part of standard practice for endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB).</p><p><strong>Objectives: </strong>We aim to analyse the proportion of non-contributive samples by EUS-FNB and to evaluate the impact of <i>KRAS</i> mutation testing on the diagnosis, theranostics and survival.</p><p><strong>Design: </strong>In this retrospective study, the impact on diagnosis and survival of <i>KRAS</i> testing for contributive and non-contributive samples by EUS-FNB was analysed.</p><p><strong>Methods: </strong>The EUS-FNB samples, combined with <i>KRAS</i> testing using the Idylla<sup>®</sup> technique on liquid-based cytology from patients with PDAC between February 2019 and May 2023, were retrospectively reviewed. The cytology results were classified according to the guidelines of the World Health Organization System for Reporting Pancreaticobiliary Cytopathology (WHOSRPC).</p><p><strong>Results: </strong>A total of 85 EUS-FNB specimens were reviewed. In all, 25 EUS-FNB samples did not lead to a formal diagnosis of PDAC according to the WHOSRPC (30.2%). Out of these 25, 11 (44%) could have been considered positive for a PDAC diagnosis thanks to the <i>KRAS</i> mutation test without carrying out further diagnosis procedures. The sensitivity of <i>KRAS</i> mutation testing using the Idylla technique was 98.6%. According to the available data, survival rates were not statistically different depending on the type of mutation.</p><p><strong>Conclusion: </strong><i>KRAS</i> mutation testing on liquid-based cytology using the Idylla or equivalent technique, combined with the PDAC EUS-FNB sample, should become a standard for diagnosis to avoid delaying treatment by doing another biopsy. Furthermore, knowledge of the <i>KRAS</i> status from treatment initiation could be used to isolate mutations requiring targeted treatments or inclusion in clinical research trials, especially for wild-type <i>KRAS</i> PDAC.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798086/pdf/","citationCount":"0","resultStr":"{\"title\":\"Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>KRAS</i> mutation research be recommended in everyday practice?\",\"authors\":\"Dominique Béchade, Lola-Jade Palmieri, Benjamin Bonhomme, Simon Pernot, Jeanne Léna, Marianne Fonck, Sophie Pesqué, Gautier Boillet, Antoine Italiano, Gilles Roseau\",\"doi\":\"10.1177/17562848231224943\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The impact of <i>KRAS</i> mutation testing on pancreatic ductal adenocarcinoma (PDAC) samples by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for reducing the need to repeat EUS-FNA has been demonstrated. Such testing however is not part of standard practice for endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB).</p><p><strong>Objectives: </strong>We aim to analyse the proportion of non-contributive samples by EUS-FNB and to evaluate the impact of <i>KRAS</i> mutation testing on the diagnosis, theranostics and survival.</p><p><strong>Design: </strong>In this retrospective study, the impact on diagnosis and survival of <i>KRAS</i> testing for contributive and non-contributive samples by EUS-FNB was analysed.</p><p><strong>Methods: </strong>The EUS-FNB samples, combined with <i>KRAS</i> testing using the Idylla<sup>®</sup> technique on liquid-based cytology from patients with PDAC between February 2019 and May 2023, were retrospectively reviewed. The cytology results were classified according to the guidelines of the World Health Organization System for Reporting Pancreaticobiliary Cytopathology (WHOSRPC).</p><p><strong>Results: </strong>A total of 85 EUS-FNB specimens were reviewed. In all, 25 EUS-FNB samples did not lead to a formal diagnosis of PDAC according to the WHOSRPC (30.2%). Out of these 25, 11 (44%) could have been considered positive for a PDAC diagnosis thanks to the <i>KRAS</i> mutation test without carrying out further diagnosis procedures. The sensitivity of <i>KRAS</i> mutation testing using the Idylla technique was 98.6%. According to the available data, survival rates were not statistically different depending on the type of mutation.</p><p><strong>Conclusion: </strong><i>KRAS</i> mutation testing on liquid-based cytology using the Idylla or equivalent technique, combined with the PDAC EUS-FNB sample, should become a standard for diagnosis to avoid delaying treatment by doing another biopsy. Furthermore, knowledge of the <i>KRAS</i> status from treatment initiation could be used to isolate mutations requiring targeted treatments or inclusion in clinical research trials, especially for wild-type <i>KRAS</i> PDAC.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798086/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848231224943\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231224943","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should KRAS mutation research be recommended in everyday practice?
Background: The impact of KRAS mutation testing on pancreatic ductal adenocarcinoma (PDAC) samples by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for reducing the need to repeat EUS-FNA has been demonstrated. Such testing however is not part of standard practice for endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB).
Objectives: We aim to analyse the proportion of non-contributive samples by EUS-FNB and to evaluate the impact of KRAS mutation testing on the diagnosis, theranostics and survival.
Design: In this retrospective study, the impact on diagnosis and survival of KRAS testing for contributive and non-contributive samples by EUS-FNB was analysed.
Methods: The EUS-FNB samples, combined with KRAS testing using the Idylla® technique on liquid-based cytology from patients with PDAC between February 2019 and May 2023, were retrospectively reviewed. The cytology results were classified according to the guidelines of the World Health Organization System for Reporting Pancreaticobiliary Cytopathology (WHOSRPC).
Results: A total of 85 EUS-FNB specimens were reviewed. In all, 25 EUS-FNB samples did not lead to a formal diagnosis of PDAC according to the WHOSRPC (30.2%). Out of these 25, 11 (44%) could have been considered positive for a PDAC diagnosis thanks to the KRAS mutation test without carrying out further diagnosis procedures. The sensitivity of KRAS mutation testing using the Idylla technique was 98.6%. According to the available data, survival rates were not statistically different depending on the type of mutation.
Conclusion: KRAS mutation testing on liquid-based cytology using the Idylla or equivalent technique, combined with the PDAC EUS-FNB sample, should become a standard for diagnosis to avoid delaying treatment by doing another biopsy. Furthermore, knowledge of the KRAS status from treatment initiation could be used to isolate mutations requiring targeted treatments or inclusion in clinical research trials, especially for wild-type KRAS PDAC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
